William Blair analyst Myles Minter has reiterated their bullish stance on XENE stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors that highlight Xenon’s promising clinical development pipeline and strategic progress. The completion of patient recruitment for the Phase III X-TOLE2 study marks a significant milestone, with data expected in early 2026. This study is crucial as it is highly powered to achieve its primary endpoint, which could lead to a New Drug Application (NDA) filing if results are positive.
Additionally, Xenon’s broader clinical efforts, including the ongoing Phase III X-ACKT study for another epilepsy indication and the initiation of studies for azetukalner in major depressive disorder and bipolar depression, underscore the company’s robust pipeline. The early-stage development of pain-targeted therapies, such as XEN1120 and XEN1701, further diversifies Xenon’s portfolio, indicating potential for future growth and value creation. These strategic developments collectively support the Buy rating, reflecting confidence in Xenon’s ability to deliver favorable outcomes and expand its market presence.
Minter covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Moderna, and Arcturus Therapeutics. According to TipRanks, Minter has an average return of 10.8% and a 48.92% success rate on recommended stocks.